Attainable predictive biomarkers for tumor reaction to mTOR inhibitors, as happen to be explained in glioblastoma, breast and prostate cancer cells, could be the differential expression of mTOR pathway proteins, PTEN, AKT, and S6.[1] Hence, this knowledge is based on preclinical assays, based on in vitro cultured tumor cell lines, https://arv-82503333.dbblog.net/1766485/5-simple-statements-about-as1842856-explained